JP2015534982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534982A5 JP2015534982A5 JP2015538060A JP2015538060A JP2015534982A5 JP 2015534982 A5 JP2015534982 A5 JP 2015534982A5 JP 2015538060 A JP2015538060 A JP 2015538060A JP 2015538060 A JP2015538060 A JP 2015538060A JP 2015534982 A5 JP2015534982 A5 JP 2015534982A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- hiv
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261715642P | 2012-10-18 | 2012-10-18 | |
| US61/715,642 | 2012-10-18 | ||
| PCT/US2013/065696 WO2014063059A1 (en) | 2012-10-18 | 2013-10-18 | Broadly-neutralizing anti-hiv antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243618A Division JP6732872B2 (ja) | 2012-10-18 | 2018-12-26 | 広域中和抗ｈｉｖ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534982A JP2015534982A (ja) | 2015-12-07 |
| JP2015534982A5 true JP2015534982A5 (enExample) | 2016-08-25 |
| JP6461804B2 JP6461804B2 (ja) | 2019-01-30 |
Family
ID=50488789
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538060A Active JP6461804B2 (ja) | 2012-10-18 | 2013-10-18 | 広域中和抗ｈｉｖ抗体 |
| JP2018243618A Active JP6732872B2 (ja) | 2012-10-18 | 2018-12-26 | 広域中和抗ｈｉｖ抗体 |
| JP2020117726A Active JP7076722B2 (ja) | 2012-10-18 | 2020-07-08 | 広域中和抗ｈｉｖ抗体 |
| JP2022075767A Active JP7376898B2 (ja) | 2012-10-18 | 2022-05-02 | 広域中和抗ｈｉｖ抗体 |
| JP2023180055A Active JP7681278B2 (ja) | 2012-10-18 | 2023-10-19 | 広域中和抗ｈｉｖ抗体 |
| JP2025075098A Pending JP2025118727A (ja) | 2012-10-18 | 2025-04-30 | 広域中和抗ｈｉｖ抗体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243618A Active JP6732872B2 (ja) | 2012-10-18 | 2018-12-26 | 広域中和抗ｈｉｖ抗体 |
| JP2020117726A Active JP7076722B2 (ja) | 2012-10-18 | 2020-07-08 | 広域中和抗ｈｉｖ抗体 |
| JP2022075767A Active JP7376898B2 (ja) | 2012-10-18 | 2022-05-02 | 広域中和抗ｈｉｖ抗体 |
| JP2023180055A Active JP7681278B2 (ja) | 2012-10-18 | 2023-10-19 | 広域中和抗ｈｉｖ抗体 |
| JP2025075098A Pending JP2025118727A (ja) | 2012-10-18 | 2025-04-30 | 広域中和抗ｈｉｖ抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10047146B2 (enExample) |
| EP (2) | EP2908912B1 (enExample) |
| JP (6) | JP6461804B2 (enExample) |
| CN (3) | CN118955699A (enExample) |
| AU (4) | AU2013331049B2 (enExample) |
| BR (1) | BR112015008635B1 (enExample) |
| CA (2) | CA3236192A1 (enExample) |
| CY (1) | CY1124405T1 (enExample) |
| DK (1) | DK2908912T3 (enExample) |
| EA (2) | EA201992107A1 (enExample) |
| ES (1) | ES2822135T3 (enExample) |
| HR (1) | HRP20201505T1 (enExample) |
| HU (1) | HUE051577T2 (enExample) |
| IL (5) | IL285049B (enExample) |
| LT (1) | LT2908912T (enExample) |
| MX (2) | MX376969B (enExample) |
| PL (1) | PL2908912T3 (enExample) |
| PT (1) | PT2908912T (enExample) |
| SI (1) | SI2908912T1 (enExample) |
| WO (1) | WO2014063059A1 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010077613A1 (en) | 2008-12-09 | 2010-07-08 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| AU2012255266B2 (en) * | 2011-05-17 | 2017-05-25 | California Institute Of Technology | Human immunodeficiency virus neutralizing antibodies and methods of use thereof |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| CA3236192A1 (en) * | 2012-10-18 | 2014-04-24 | The Rockefeller University | Broadly-neutralizing anti-hiv antibodies |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| AU2014224049B2 (en) * | 2013-02-28 | 2018-11-29 | Therabiol, Inc. | HIV antigens and antibodies |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US10093720B2 (en) | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
| EP4140485A1 (en) * | 2014-07-11 | 2023-03-01 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
| EA201790369A1 (ru) | 2014-09-16 | 2017-10-31 | Джилид Сайэнс, Инк. | Твердые формы модулятора толл-подобного рецептора |
| US20170267784A1 (en) | 2014-10-23 | 2017-09-21 | Singh Molecular Medicine, Llc | Single domain antibodies directed against intracellular antigens |
| WO2016149698A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies) |
| RU2757135C2 (ru) | 2015-09-24 | 2021-10-11 | АБВИТРО ЭлЭлСи | Композиции антител к вич и способы их применения |
| TWI746473B (zh) * | 2015-11-02 | 2021-11-21 | 美商辛分子醫藥有限公司 | 針對細胞內抗原之單域抗體 |
| WO2018002902A1 (en) | 2016-07-01 | 2018-01-04 | Glaxosmithkline Intellectual Property (No.2) Limited | Antibody-drug conjugates and therapeutic methods using the same |
| WO2018075564A1 (en) | 2016-10-17 | 2018-04-26 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
| EP3529263B1 (en) | 2016-10-21 | 2025-08-06 | Altor BioScience Corporation | Multimeric il-15-based molecules |
| AU2017387041B2 (en) * | 2016-12-27 | 2024-12-12 | California Institute Of Technology | Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof |
| WO2019118266A1 (en) | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| WO2019165122A1 (en) * | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| US11311603B2 (en) | 2018-06-19 | 2022-04-26 | Nantcell, Inc. | HIV treatment compositions and methods |
| CR20200653A (es) | 2018-07-03 | 2021-02-11 | Gilead Sciences Inc | Anticuerpos que se dirigen al gp120 de vih y métodos de uso |
| US20210292396A1 (en) * | 2018-07-27 | 2021-09-23 | International Aids Vaccine Initiative | Enginerred antibodies to hiv env |
| JP2022500042A (ja) * | 2018-09-14 | 2022-01-04 | ザ ロックフェラー ユニバーシティー | 抗ｈｉｖ抗体１０−１０７４バリアント |
| CN113710689B (zh) * | 2019-01-28 | 2025-05-06 | 修普霍斯生物科学有限公司 | 选择性地将附着的异源分子递送至car细胞上的非天然nkg2d受体的修饰的非天然nkg2d配体 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| LT3938047T (lt) | 2019-03-22 | 2022-10-10 | Gilead Sciences, Inc. | Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje |
| EP3947445A1 (en) * | 2019-04-04 | 2022-02-09 | Vanderbilt University | Hiv/hcv cross-reactive antibodies and uses thereof |
| TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| CN112759651B (zh) * | 2019-11-01 | 2022-09-20 | 北京华夏清医治疗科技有限公司 | 一种包含嵌合抗原受体修饰的t细胞及其应用 |
| EP3831848A1 (en) * | 2019-12-02 | 2021-06-09 | Universität zu Köln | Broadly neutralizing antibodies against hiv |
| JP7711068B2 (ja) | 2019-12-24 | 2025-07-22 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| JP7712352B2 (ja) | 2020-08-07 | 2025-07-23 | ギリアード サイエンシーズ， インコーポレイテッド | ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用 |
| MX2023002194A (es) | 2020-08-25 | 2023-03-03 | Gilead Sciences Inc | Moleculas multiespecificas de union a antigenos dirigidas al vih y metodos de uso. |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4660325A3 (en) | 2020-11-11 | 2026-02-25 | Gilead Sciences, Inc. | Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2023102529A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| KR20240113832A (ko) | 2021-12-03 | 2024-07-23 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염 치료용 화합물 |
| PL4445900T3 (pl) | 2021-12-03 | 2025-09-22 | Gilead Sciences, Inc. | Związki terapeutyczne przeciwko zakażeniu wirusem hiv |
| CN118475353A (zh) | 2021-12-17 | 2024-08-09 | Viiv保健公司 | 用于hiv感染的联合疗法及其用途 |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| JP2025523043A (ja) | 2022-07-12 | 2025-07-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用 |
| KR20250051732A (ko) | 2022-08-26 | 2025-04-17 | 길리애드 사이언시즈, 인코포레이티드 | 광범위 중화 항체를 위한 투여 및 일정 요법 |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| CN121358478A (zh) | 2023-04-19 | 2026-01-16 | 吉利德科学公司 | 衣壳抑制剂的给药方案 |
| US20250011352A1 (en) | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Solid forms |
| WO2024249592A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Quinazolinyl-indazole derivatives as therapeutic compounds for hiv |
| AU2023460182A1 (en) | 2023-07-28 | 2026-02-05 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| AU2023462614A1 (en) | 2023-08-23 | 2026-03-19 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025050404A1 (zh) * | 2023-09-08 | 2025-03-13 | 成都维瑾柏鳌生物医药科技有限公司 | 一种药物组合物及其应用 |
| TW202530227A (zh) | 2023-10-11 | 2025-08-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025080850A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080879A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184609A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US81A (en) | 1836-11-15 | Erawijjg | ||
| US6593A (en) | 1849-07-17 | Cutting | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5798251A (en) * | 1990-05-29 | 1998-08-25 | Cedars-Sinai Medical Center | Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120 |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| WO1996016673A1 (en) | 1994-12-02 | 1996-06-06 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| JP2005510201A (ja) | 2001-01-26 | 2005-04-21 | アブジェニックス インコーポレイテッド | Ｈｉｖ−１に対する中和ヒトモノクローナル抗体、それらの産生および使用 |
| CA2485120C (en) * | 2002-05-06 | 2013-02-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
| US7501494B2 (en) * | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| EP1613953A4 (en) * | 2003-04-14 | 2006-09-06 | Children S Nat Medical Ct Inc | ANTIRETROVIRAL ANALYSIS BY MASS SPECTROMETRY |
| WO2005058963A1 (ja) * | 2003-12-16 | 2005-06-30 | Kumamoto Technology And Industry Foundation | 抗ｈｉｖ抗体 |
| CN1910289B (zh) * | 2004-01-07 | 2012-05-23 | 日立化成研究中心公司 | 用于检测hiv的引物和探针 |
| JP4895727B2 (ja) * | 2006-08-28 | 2012-03-14 | シスメックス株式会社 | 抗ｈｉｖ抗体検出試薬、試薬キット、試薬の製造方法、及び抗ｈｉｖ抗体の検出方法 |
| WO2008140579A2 (en) | 2006-11-17 | 2008-11-20 | New York University | Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
| WO2009015247A2 (en) * | 2007-07-23 | 2009-01-29 | Maxygen, Inc. | Chimeric hiv antigens |
| RU2011129765A (ru) * | 2008-12-19 | 2013-01-27 | Эбботт Лэборетриз | Молекулярный тест, используемый для диагностики вич тропизма |
| WO2011092593A2 (en) * | 2010-01-20 | 2011-08-04 | Institute For Research In Biomedicine | Hiv-1 neutralizing antibodies and uses thereof |
| RU2535034C2 (ru) | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
| EP4549461A3 (en) * | 2010-08-31 | 2025-08-06 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
| WO2012074863A2 (en) * | 2010-12-01 | 2012-06-07 | Albert Einstein College Of Medicine Of Yeshiva University | Constructs and methods to identify antibodies that target glycans |
| CA3236192A1 (en) | 2012-10-18 | 2014-04-24 | The Rockefeller University | Broadly-neutralizing anti-hiv antibodies |
-
2013
- 2013-10-18 CA CA3236192A patent/CA3236192A1/en active Pending
- 2013-10-18 WO PCT/US2013/065696 patent/WO2014063059A1/en not_active Ceased
- 2013-10-18 HR HRP20201505TT patent/HRP20201505T1/hr unknown
- 2013-10-18 LT LTEP13847347.5T patent/LT2908912T/lt unknown
- 2013-10-18 JP JP2015538060A patent/JP6461804B2/ja active Active
- 2013-10-18 DK DK13847347.5T patent/DK2908912T3/da active
- 2013-10-18 CN CN202410516500.4A patent/CN118955699A/zh active Pending
- 2013-10-18 CA CA2888659A patent/CA2888659C/en active Active
- 2013-10-18 EA EA201992107A patent/EA201992107A1/ru unknown
- 2013-10-18 ES ES13847347T patent/ES2822135T3/es active Active
- 2013-10-18 HU HUE13847347A patent/HUE051577T2/hu unknown
- 2013-10-18 IL IL285049A patent/IL285049B/en unknown
- 2013-10-18 CN CN201380064622.4A patent/CN104918658B/zh active Active
- 2013-10-18 MX MX2015004924A patent/MX376969B/es active IP Right Grant
- 2013-10-18 CN CN202110092787.9A patent/CN112920269B/zh active Active
- 2013-10-18 US US14/436,608 patent/US10047146B2/en active Active
- 2013-10-18 EA EA201590741A patent/EA035012B1/ru unknown
- 2013-10-18 BR BR112015008635-7A patent/BR112015008635B1/pt active IP Right Grant
- 2013-10-18 EP EP13847347.5A patent/EP2908912B1/en active Active
- 2013-10-18 EP EP20182718.5A patent/EP3783018A1/en active Pending
- 2013-10-18 PL PL13847347T patent/PL2908912T3/pl unknown
- 2013-10-18 PT PT138473475T patent/PT2908912T/pt unknown
- 2013-10-18 IL IL301018A patent/IL301018B1/en unknown
- 2013-10-18 AU AU2013331049A patent/AU2013331049B2/en active Active
- 2013-10-18 SI SI201331809T patent/SI2908912T1/sl unknown
-
2015
- 2015-04-16 IL IL238320A patent/IL238320B/en unknown
- 2015-04-16 MX MX2020011669A patent/MX2020011669A/es unknown
-
2018
- 2018-06-12 US US16/006,420 patent/US10392433B2/en active Active
- 2018-12-26 JP JP2018243618A patent/JP6732872B2/ja active Active
-
2019
- 2019-02-14 AU AU2019201039A patent/AU2019201039B2/en active Active
- 2019-07-10 US US16/507,867 patent/US11142564B2/en active Active
-
2020
- 2020-07-08 JP JP2020117726A patent/JP7076722B2/ja active Active
- 2020-09-28 AU AU2020244391A patent/AU2020244391B2/en active Active
- 2020-10-21 CY CY20201100995T patent/CY1124405T1/el unknown
-
2021
- 2021-09-09 US US17/470,184 patent/US11649276B2/en active Active
-
2022
- 2022-05-02 JP JP2022075767A patent/JP7376898B2/ja active Active
- 2022-05-25 IL IL293362A patent/IL293362B2/en unknown
-
2023
- 2023-03-29 AU AU2023201926A patent/AU2023201926B2/en not_active Expired - Fee Related
- 2023-04-07 US US18/297,301 patent/US12338277B2/en active Active
- 2023-10-19 JP JP2023180055A patent/JP7681278B2/ja active Active
-
2025
- 2025-04-30 JP JP2025075098A patent/JP2025118727A/ja active Pending
- 2025-05-09 US US19/203,424 patent/US20250320280A1/en active Pending
- 2025-09-15 IL IL323371A patent/IL323371A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534982A5 (enExample) | ||
| RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
| JP2019536806A5 (enExample) | ||
| JP2011528902A5 (enExample) | ||
| JP2012504955A5 (enExample) | ||
| JP2014512809A5 (enExample) | ||
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| JP2018535650A5 (enExample) | ||
| JP2010516229A5 (enExample) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2018521638A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| HRP20231196T1 (hr) | Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba | |
| JP2014511179A5 (enExample) | ||
| JP2020508303A5 (enExample) | ||
| JP2018035138A5 (enExample) | ||
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2018527952A5 (enExample) | ||
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2015503909A5 (enExample) | ||
| RU2010120879A (ru) | Антитела против g-белка распираторно-синцитиального вируса (rsv) | |
| RU2015129813A (ru) | Антитела, которые связываются с лигандом запрограммированной клеточной смерти 1 (pd-l1) | |
| JP2016507470A5 (enExample) | ||
| JP2025131696A5 (enExample) |